- Previous Close
0.3300 - Open
0.3300 - Bid 0.3280 x --
- Ask 0.3490 x --
- Day's Range
0.3000 - 0.3580 - 52 Week Range
0.1400 - 1.1450 - Volume
377,612 - Avg. Volume
345,631 - Market Cap (intraday)
45.286M - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.70
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction. In addition, its pre-clinical product is Sirolimus for prevention of organ transplant rejection. Further, the company focuses on the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquatered in Uppsala, Sweden.
www.klaria.com5
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: KLAR.ST
View MorePerformance Overview: KLAR.ST
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KLAR.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KLAR.ST
View MoreValuation Measures
Market Cap
42.82M
Enterprise Value
60.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
52.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-4.34%
Return on Equity (ttm)
-109.48%
Revenue (ttm)
-6.53M
Net Income Avi to Common (ttm)
-44.58M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
496k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-59.13M